Scandion Oncology

Overcoming cancer drug resistance

The liquidator of Scandion Oncology (the "Company") has today submitted an application for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's shares on Nasdaq First North Growth Market will be announced as soon as the Company has received confirmation from Nasdaq. On March 27, 2025, the Annual General Meeting of the Company resolved on voluntary liquidation in accordance with Chapter 14 of the Danish Companies Act. The estimated time for final distribution of assets is H2 2025. For further information, please contact:Appointed LiquidatorPhone: +45 21227227E-mail: info@scandiononcology.com The information was provided by the contact person above for publication on 25 June, 2025 at 14.00 CET. About Scandion Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Vator Securities is the Company's certified advisor on Nasdaq First North Growth Market. AttachmentsScandion Oncology Has Applied For Delisting Of The Company's Shares From Nasdaq First North Growth Market Scandion Oncology Has Applied For Delisting Of The Company’s Shares From Nasdaq First North Growth Market

The Annual General Meeting 2025 of Scandion Oncology A/S in liquidation (the "Company") was held on 27 March 2025 at 2:00 p.m. All proposals were adopted in accordance with the notice. As such, the Company has now entered into voluntary solvent liquidation. The appointed liquidator will initiate the winding down of the Company. The full minutes of the annual general meeting are attached to this announcement. The agenda of the annual general meeting was as follows: Election of chairman of the meeting Report from the board of directors on the Company's business in the past year Presentation of the audited annual report for approval Proposal of notice of discharge to the board of directors and the executive board Decision on appropriation of profit or loss as recorded in the approved annual report Proposal to enter into voluntary solvent liquidation Proposal to elect a liquidator Proposal to approve the board of directors' fee for Q1 2025 Election of members of the board of directors (removed) Election of auditor Any other business For further information, please contact:Appointed LiquidatorPhone: +45 21227227E-mail: info@scandiononcology.com The information was provided by the contact person above for publication on 27 March 2025 at 16.00 CET. About Scandion Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Vator Securities is the Company's certified advisor on Nasdaq First North Growth Market. AttachmentsScandion Oncology Announce Results Of Annual General Meeting 2025Scandion Oncology Minutes Of Annual General Meeting 2025 Scandion Oncology Announce Results Of Annual General Meeting 2025Scandion Oncology Minutes Of Annual General Meeting 2025